VolitionRx Limited Awarded an Additional $1.4 Million in Non-Dilutive Funding
VolitionRx Limited Announces First Quarter 2019 Financial Results and Business Update
VolitionRx Limited Executes a Contract for Clinical Trial Program in Lung Cancer
VolitionRx Limited Schedules First Quarter 2019 Earnings Conference Call and Business Update
VolitionRx Limited Hosts Capital Markets Day at the New York Stock Exchange and Issues Company Update Report
VolitionRx Limited Signs Memorandum of Understanding with Texas A&M University for Potential Collaboration to Develop Nu.QTM Veterinary Diagnostics
VolitionRx Limited Extends Clinical Trial Program in Lung Cancer
VolitionRx Limited Signs Memorandum of Understanding with Fosun Long March in China
VolitionRx Limited to Present at Conferences in March & April 2019
VolitionRx Limited to Present at Conferences in the U.S. Next Week
